Market Overview

Repligen Receives First Milestone Payment from Pfizer for Development of Treatment for SMA

Share:
Related RGEN
10 Stocks That Rallied Four Days, Then Sold Off Yesterday
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Notable earnings before Wednesday's open (Seeking Alpha)
Related PFE
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Boeing, Pfizer And Others Band Together To Ask Congress For More Taxes
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug (Investor's Business Daily)

Repligen Corporation (Nasdaq: RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. (NYSE: PFE) under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to treat spinal muscular atrophy (SMA). This first milestone payment was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations by Repligen. Repligen announced the Agreement in January of this year, at which time it received an upfront payment of $5 million. Repligen remains eligible to receive up to $64 million in additional success-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement.

Posted-In: News

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!